Physician profile
James Wolfe
NPI 1912985094
$2,461.50
in general payments reported to CMS, 2019-2025
23 companies · $216 in 2025
The $216 reported for 2025 was less than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $779 · 2020: $254 · 2021: $377 · 2022: $381 · 2023: $293 · 2024: $160 · 2025: $216.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $669.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $669.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $1,116.05 | 2019-2025 | Xtampza, Belbuca |
| Pfizer INC. | $433.54 | 2019-2021 | |
| Boston Scientific Corporation | $207.04 | 2021-2025 | General - Therapies |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $145.97 | 2019-2023 | Relistor |
| Daiichi Sankyo INC. | $116.47 | 2019 | |
| Abbvie INC. | $59.67 | 2021-2023 | Botox |
| Scilex Pharmaceuticals INC. | $57.14 | 2019 | |
| Biodelivery Sciences International, INC. | $48.04 | 2019-2020 | |
| Assertio Therapeutics, INC. | $44.71 | 2019 | |
| Si-Bone, INC. | $36.71 | 2022 | |
| Lundbeck LLC | $24.16 | 2022 | |
| Grt US Holding, INC. | $19.25 | 2021 | |
| Protega Pharmaceutials INC | $18.09 | 2023 | Roxybond |
| Amgen INC. | $16.82 | 2019 | |
| Allergan, INC. | $14.97 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pacira Pharmaceuticals Incorporated | $14.83 | 2023 | Iovera, Zilretta |
| Shionogi INC | $14.14 | 2019 | |
| Pernix Therapeutics Holdings, INC. | $13.82 | 2019 | |
| Mdd US Operations, LLC | $13.52 | 2019 | |
| Bioventus LLC | $13.06 | 2021 | |
| Horizon Therapeutics Plc | $11.55 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $11.04 | 2020 | |
| Zyla Life Sciences, INC. | $10.91 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Wolfe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.